Strategic Medicine’s management team has extensive experience in all facets of biotechnology and healthcare. Team members have demonstrated success in developing breakthrough technologies and building successful organizations.

Dr. Michael N. Liebman, Managing Director

Michael N. Liebman, Ph.D. is the Managing Director of Strategic Medicine after serving as the Executive Director of the Windber Research Institute since November, 2003.

Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center since September, 2000. He served as Global Head of Computational Genomics at Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals. He was also Director of Genomics for Vysis, Inc and Director of Bioinformatics at the Amoco Technology Company. He has served on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics.

Dr. Liebman serves on 14 international scientific advisory boards consults for 5 pharma/biotech companies and has been on the economic development programs in the Philadelphia Life Sciences Sector and the State of Illinois Biotechnology Commission. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and is currently on the Human Health and Medicinal Chemistry Commission of the IUPAC.

Michael N. Liebman received his PhD in protein crystallography and theoretical chemistry. His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and their quality of life.

Recent activities also include computational approaches to drug safety and toxicology with specific emphasis on reducing animal testing.